Boardroom Talk: Summit Therapeutics' long road to drug approval
Investors' Chronicle - A podcast by Investors' Chronicle - Venerdì
Categorie:
Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates. Hosted on Acast. See acast.com/privacy for more information.
